Argentinian pharma company Biosidus and Crystec have announced a new deal for development of dry powder formulations of Biosidus drugs for inhaled and/or nasal delivery using Crystec’s mSAS supercritical fluid particle engineering technology. The first project for the two companies under the new agreement will be development of a dry powder formulation of teriparatide for the treatment of osteoporosis.
Biosidus Scientific Director Marcelo Criscuolo commented, “We are passionate about making our vital therapies accessible and convenient for those who require them. Our ultimate ambition is to eliminate the need for daily injections meaning that men, women and children who suffer from long term and chronic illnesses are not subjected to additional discomfort in the course of their treatment. Working with Crystec’s innovative mSAS technology opens up the possibility of maximizing the therapeutic potential of these drugs through retaining improved biological activity levels and enabling ‘needle free’ delivery options for our patients.”
Crystec CEO Paul Thorning said, “We are delighted to work with Biosidus in this important area of drug delivery. Our collaboration provides significant potential to demonstrate the power of the mSAS platform in simplifying biopharmaceutical processing, whilst facilitating the accelerated development of inhaled and nasal products that could be truly transformative for patients.”
Read the Crystec and Biosidus press release.
